Author Archive: Brett Owens

Healthcare stocks are selling off with the turbulence in the Middle East.

But, why? The best plays here are geopolitical-proof. They print money regardless of what’s going on in the world.

So this is a good time to check in on healthcare. In a moment we’ll review five dividends between 6.0% and, get this, 14.1%!

First, though, let’s unpack the reasons for the recent pullback. Back in August, I flagged how Medicaid cuts, health research funding, pharmaceutical tariffs and a cocktail of other headwinds had kept the sector pinned down for months. However these resilient companies have a habit of getting back up—and sure enough, healthcare went on a new tear, returning about 25% through late February.… Read more

Be careful how you buy your bonds. The most popular tickers have four “fatal flaws” that’ll doom you to underperformance at best, or at worst leave you hanging in the event of a market meltdown!

Let’s pick on the widely followed and owned iShares iBoxx High Yield Corporate Bond ETF (HYG) as an example. It has attracted over $15 billion in assets because:

1. It’s convenient and as easy to buy as a stock.
2. It’s diversified (for better or worse, as we’ll see shortly) with 1,327 individual holdings.
3. It pays well, at nearly 6% today.

The accessibility of funds like HYG appears cute and comfortable enough.… Read more

The bombs continue to fall in the Middle East. But we contrarians know something the crowd always forgets at times like this:

The world is always burning somewhere.

At times like these, our Contrarian Income Report dividend strategy shines. Our portfolio yields 8.2% on average, and those dividends roll in no matter what the world throws at us.

The result? No need to sell into a downturn to get the cash we need. And we get the chance to go on offense, too, snagging dividends on the dips and boosting our income stream (and upside potential) as we do.

Rinse and repeat.… Read more

This high-yield sector is being taken to the woodshed by the Wall Street spreadsheet jockeys this year.

The contrarian opportunity? Big yields up to 15.6% in BDC Land. Some of these deals are trading for as little as 72 cents on the dollar.

Which means opportunists like us have been handed something rare: wild yields of 11% to 15.6% for as little as 72 cents on the dollar.

Business development companies (BDCs) are “Main Street bankers” because they do what Wall Street won’t: provide capital to small and midsized businesses that the big banks either ignore entirely, or won’t touch without demanding a firstborn as collateral.… Read more

$500K can be enough money to retire on. Even as early as age 50!

The trick is to convert the pile of cash into cash flow that can pay the bills. I’m talking about $40,574.93 per year in dividend income on that nest egg, thanks to 8%+ average yields.

These are passive payouts that show up every quarter or, in many cases, every month.

Meanwhile, we keep that $500K nest egg intact. Or, better yet, grind that principal higher steadily and safely.

Got more in your retirement account? Cool—more monthly dividend income for you!

We’ll talk specific stocks, funds and yields in a moment.… Read more

One thing is clear from the last few weeks: The geopolitical chaos never stops.

We contrarians get that. But the first-level crowd does not. When we’re hit with a war, snap tariffs or a pandemic (ugh!), most investors panic.

And the truth is, chaos—whether it’s war in Iran or fears that AI will erase whole industries—is coming at us faster than ever.

Most people think they can handle this wave of worry. But it pays to remember the famous Mike Tyson quote: “Everyone has a plan until they get punched in the face.”

True in life and investing. It’s just another way of saying that the same investors who think they can handle the latest “punch in the face” are often the first to turtle and sell low.… Read more

What’s better than getting to buy 6.6%-11% yields at discounted prices?

How about snapping those sweet dividend payers while momentum is on your side?

Late in 2025, I wrote about a “small-cap reawakening”—a bullish tailwind from retreating Federal Reserve rates that had begun to propel smaller companies forward and could continue well into 2026.

So far, so true. Small- and mid-cap stocks (or “SMIDs”) alike have been cruising full sail ahead while their larger cousins have been dead in the water.

2026 Has Been a Reversal of Longstanding Large-Cap Dominance

Better still for you if you haven’t yet taken the plunge into Wall Street’s more diminutive stocks: Small caps’ hot start has done little to drive up valuations.… Read more

Last month, we hit the contrarian karaoke bar together. No judgment. It was a good time!

If you’ve got a (ahem, no judgment) fuzzy memory, well, here’s how it went down. We sang some Billy Joel—good start, I know.

A little We Didn’t Start the Fire. We honored his point that the chaos never stops. That was the case in 1989 when the banger topped the Billboard charts. It remains true today.

Ha, we even belted a 2026 verse over our (virtual) beers!

Venezuela, Davos snow, Iran missiles here we go

Greenland borders, tariff fights, Powell keeping money tight

Wow.… Read more

Wall Street is mired in another panic over AI. And we contrarians are here for it.

Our play? As always, we’re going where first-level investors aren’t, quietly snapping up dividends AI is set to supercharge.

I’m talking specifically about an overlooked opportunity in drug stocks, which are about to see the value of their R&D dollars get a big boost from AI. We’re going to tap in with an 8.8%-yielding closed-end fund (CEF) that’s trading for 11.4% below its “true” value.

That discount exists in part because investors—worried about how AI may disrupt sectors like software—are ignoring pharma, and the accelerated product cycles (and cash flows!)… Read more

“Time out.” I yelled it with a hint of disgust. I didn’t even have to make eye contact with my assistant coach—we were on the same page.

We’d just watched the second air-ball three-pointer of the second half.

“Get in there for Reese.”

Reese shrugged and jogged off the court. I grabbed him lovingly by the shoulders. “Hey buddy — do you know why you’re out?”

He nodded slowly. “Because…I…shot… a…three…pointer.”

“And what did I just say in the huddle?”

“…To…not…shoot…three…pointers.”

I patted him on the shoulder. Reese was back in the game in two minutes. But I had to make the point.… Read more